Conexeu Sciences Names Daniel M. Bradbury Chairman

Bradbury's appointment as Chairman takes effect December 1, 2026, replacing Jeff Sharpe, who stepped down from the role.

Updated on Nov. 19, 2026 in Business

Isometric editorial illustration of a single high-backed walnut chair at the head of a long oak table in a bare room, in muted oxblood, teal, and cream.
Conexeu Sciences Inc. named veteran life sciences executive Daniel M. Bradbury as Chairman of its Board, replacing Jeff Sharpe, effective December 1, 2026. AI Illustration. Upload story photo >

Conexeu Sciences Inc. has appointed Daniel M. Bradbury as Chairman of its Board of Directors, effective December 1, 2026. Jeff Sharpe stepped down as Chairman and Director to make way for the appointment.

Why it matters

The change puts a veteran life sciences executive at the head of a recently listed preclinical medical device company that plans a 510(k) submission in early 2027. Bradbury's governance background may shape the board's oversight as the company advances its regulatory strategy.

Bradbury previously served as President and CEO of Amylin Pharmaceuticals from March 2007 until August 2012, when Bristol-Myers Squibb acquired the company in a transaction valued at approximately $7 billion. Conexeu, which listed on Nasdaq in May 2026, plans a 510(k) submission in the first calendar quarter of 2027.

The players

Conexeu Sciences Inc.

A preclinical-stage medical device company that listed on Nasdaq in May 2026 and is targeting wound care, periodontal and soft-tissue applications.

Daniel M. Bradbury

A life sciences executive with about 40 years of experience building companies, including an 18-year tenure at Amylin Pharmaceuticals and roles at SmithKline Beecham.

Jeff Sharpe

The former Chairman and Director of Conexeu Sciences Inc. who stepped down to make way for Bradbury's appointment.

The details

Conexeu Sciences Inc. announced from Reno, Nevada that its Board appointed Daniel M. Bradbury as Chairman, with Jeff Sharpe stepping down as Chairman and Director to make way for the change. Bradbury is also Chairman and Co-Founder of Equillium, Inc., Chairman of the Board of Castle Biosciences, Inc., and an independent director of Vivani Medical, Inc. and Biocon Limited.

Timeline

  1. May 2026: Conexeu Sciences listed on Nasdaq.

  2. October 2025: Bradbury ended his Executive Chairman role at Equillium.

  3. December 1, 2026: Bradbury's Chairman appointment takes effect.

  4. First calendar quarter of 2027: Conexeu plans its anticipated 510(k) submission for its initial indication.

Market Landscape

Bradbury's leadership of Amylin, which Bristol-Myers Squibb acquired for roughly $7 billion in 2012, gives Conexeu's board a precedent of a mid-sized biopharma company reaching a major acquisition. The appointment places an experienced executive with that track record at the head of a newly public device company competing in wound care and soft-tissue markets.

For investors holding Conexeu shares after its May 2026 Nasdaq listing, the board change signals new oversight leadership ahead of the planned 2027 regulatory filing. Reader impact on consumers is limited, since the company has not yet brought a product to market.

The takeaway

Leadership changes at early-stage device companies often set the tone for regulatory and financing decisions in the years that follow. Watching how Bradbury's board guides the company toward its 2027 submission will show whether the appointment shifts its strategy.

What happens next

Bradbury's Chairman appointment takes effect December 1, 2026, and Conexeu plans its 510(k) submission in the first calendar quarter of 2027.

Further reading

Explore more People coverage tied to corporate leadership changes in the business sector.

Source note: This article includes information reported by The Manila times.